Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
- 11 January 2022
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (6) , 3823-3830
Abstract
Background Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the present study is to explore the evolution of patients affected by CM and MOH at the baseline, after erenumab discontinuation. Methods One hundred and eighty-five patients affected by CM and MOH were recruited and followed up after erenumab discontinuation. The number of migraine days per month, the number of painkillers taken per month, the number of days in which one medication was used for a month were collected every 30 days for the 3 months following erenumab suspension. Results At the 3rd month after suspension, patients displayed a significantly higher number of migraine days per month, a significantly higher painkiller consumption, and a significantly higher migraine-related disability. A high body mass index and the presence of aura were positively correlated with the relapse of CM and MOH. Conclusion Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation.Keywords
This publication has 25 references indexed in Scilit:
- Cortical spreading depression as a site of origin for migraine: Role of CGRPCephalalgia, 2018
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Medication-overuse headache: risk factors, pathophysiology and managementNature Reviews Neurology, 2016
- Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responsesCephalalgia, 2016
- Treatment of medication-overuse headache: A systematic reviewCephalalgia, 2015
- Critical role of calcitonin gene-related peptide receptors in cortical spreading depressionProceedings of the National Academy of Sciences, 2012
- Migraine ChronificationCurrent Neurology and Neuroscience Reports, 2011
- Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia, 2010
- The Migraine Disability Assessment (MIDAS) Questionnaire: Translation and Reliability of the Italian VersionCephalalgia, 2001